接受抗肿瘤坏死因子治疗的炎症性肠病患者的关节表现
这项回顾性单中心研究纳入2013年2月至2017年5月在本院因炎症性肠病接受抗肿瘤坏死因子(TNF)治疗的442例患者,115例(26%)在平均20(±22)个月治疗后出现新发关节表现,其中59例(13.3%)为炎症性表现;炎症性表现中39%为矛盾性关节表现,27%与炎症性肠病 flare 相关,27%与抗TNF免疫化相关,7%为其他诊断。矛盾性关节表现在16例(70%)患者中虽继续抗TNF治疗仍自行缓解。
要点
- 因炎症性肠病接受抗TNF治疗的患者中约13%出现炎症性关节表现。
- 炎症性关节表现中超过四分之一与抗TNF免疫化相关,原文认为此情形下应检查免疫化。
- 约40%炎症性关节表现为矛盾性表现,多数为一过性且无需停用抗TNF。
核心结论
- 因炎症性肠病接受抗TNF治疗的患者中约13%出现炎症性关节表现。
- 超过四分之一与抗TNF免疫化相关,原文认为此情形下应检查免疫化。
- 约40%为矛盾性表现,多数为一过性且无需停用抗TNF。
研究设计与样本
- 回顾性单中心研究,纳入本院所有因炎症性肠病接受抗TNF治疗的患者。
- 2013年2月至2017年5月共纳入442例患者(年龄36.2±15岁,男性50.5%):克罗恩病277例、溃疡性结肠炎154例、未定型结肠炎11例。
- 分析治疗期间所有新发关节表现,并将有矛盾性关节表现的患者与无炎症性关节表现的患者进行比较。
主要发现
- 115例(26%)患者在平均20(±22)个月治疗后出现新发关节表现。
- 其中59例(13.3%)为炎症性表现:矛盾性占39%,与炎症性肠病 flare 伴随占27%,与抗TNF免疫化相关占27%,其他诊断占7%。
- 矛盾性关节表现中19例(83%)为新发关节症状,包括8例(35%)新发脊柱关节炎。
- 矛盾性关节表现无预测因素。
- 矛盾性表现在16例(70%)患者中虽继续抗TNF治疗仍自行缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe and identify factors associated with articular manifestations occurring in patients treated with anti-tumour necrosis factor (TNF) for inflammatory bowel diseases (IBDs). METHODS: Retrospective monocentric study, including all patients who received an anti-TNF for an IBD in our hospital. All incident articular manifestations occurring during treatment were analysed. Characteristics of patients with paradoxical articular manifestations were compared with that of patients without inflammatory articular manifestations. RESULTS: Between February 2013 and May 2017, we identified 442 patients (36.2±15 years, 50.5% men) who had ever received an anti-TNF for an IBD: Crohn's disease (n=277), ulcerative colitis (n=154) and undetermined colitis (n=11). 115 (26%) patients developed new articular manifestations after a mean of 20 (±22) months of treatment. Among them, 59 (13.3%) had inflammatory manifestations: paradoxical in 39%, concomitant of an IBD flare in 27%, linked to an immunisation against anti-TNF in 27% and 7% to another diagnosis. Among paradoxical articular manifestations, 19 (83%) were new articular symptoms, including 8 (35%) de novo spondyloarthritis. There were no predictive factors of paradoxical articular manifestation. Paradoxical manifestations spontaneously resolved in 16 (70%) patients despite continuation of anti-TNF. CONCLUSION: Inflammatory articular manifestations occurred in about 13% of patients treated with anti-TNF for IBD. More than a quarter were linked to an immunisation against anti-TNF, which has to be searched in this situation. About 40% were paradoxical. In most of cases, they were transitory and did not require anti-TNFs discontinuation.
引用
- Cachen L, Nocturne G, Collins M, et al. Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF. RMD Open. 2022. PMID: 35091460. doi:10.1136/rmdopen-2021-001697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。